Skip to main content
Mega Genomics Limited logo

Mega Genomics Limited — Investor Relations & Filings

Ticker · 6667 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 317 across all filing types
Latest filing 2025-08-29 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 6667

About Mega Genomics Limited

https://www.megagenomics.cn

Mega Genomics Limited operates as a genetic testing platform company focused on providing consumer genetic testing and cancer screening services. The core business involves delivering comprehensive genetic analysis solutions to the consumer market. Key product offerings include advanced sequencing packages such as Personal Whole Genome Sequencing, which analyzes over 700,000 genetic loci to assess disease risk and provide pharmacogenomic recommendations. Additionally, the company offers Adult and Children's Whole Exome Sequencing packages, which analyze over 180,000 key exome regions to evaluate risks for high-risk diseases, hereditary cancers, and complex genetic disorders, alongside personalized guidance on drug efficacy, nutrition, and fitness.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION - DELAY IN PUBLICATION OF 2025 INTERIM RESULTS AND CONTINUED SUSPENSION OF TRADING
Report Publication Announcement Classification · 1% confidence The document is an announcement under Listing Rules regarding the delay in publication of the company’s 2025 interim results and continued suspension of trading. It does not contain the interim financial statements themselves but only notifies shareholders of timing changes. It is therefore not the interim report (IR) but a report publication announcement. Accordingly, it should be classified as RPA.
2025-08-29 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025
Regulatory Filings Classification · 1% confidence The document is a routine monthly return filed with the Hong Kong Stock Exchange (HKEX) under Chapter 19B of the Listing Rules, detailing movements in authorised share capital, issued shares, treasury shares, and confirming compliance with listing rules. It is not an annual or interim financial report, not a dividend or voting result announcement, nor a share issuance notice of a specific event. This is a regulatory submission that does not fit the more specific categories, so it should be classified under the fallback “Regulatory Filings” (RNS).
2025-08-04 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, 21 JULY 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an announcement by Mega Genomics Limited of the poll results at its Extraordinary General Meeting held on 21 July 2025. It lists each resolution put to a vote, the votes for and against, and confirms that the resolutions were duly passed. This clearly constitutes a declaration of voting results at a shareholders’ meeting, matching the definition for 'Declaration of Voting Results & Voting Rights Announcements' (Code: DVA).
2025-07-21 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025
Regulatory Filings Classification · 1% confidence The document is an FF301 form filed with HKEX – a monthly return under Chapter 19B listing rules detailing movements in authorised and issued share capital. It is not a one‐off share issue notice, earnings release, AGM material, or annual/interim report, but a routine regulatory filing. Hence it falls into the general “Regulatory Filings” category (RNS).
2025-07-04 English
NOTICE OF EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal Notice of Extraordinary General Meeting (EGM) sent to shareholders, detailing meeting date, resolutions to be voted on, proxy appointment procedures, and voting logistics. It is not the meeting results, annual report, or financial statements. Under the provided definitions, materials circulated to shareholders to request votes and provide information on upcoming corporate meetings fall under “Proxy Solicitation & Information Statement (Code: PSI)”.
2025-06-30 English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON 21 JULY 2025
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form of Proxy for an Extraordinary General Meeting scheduled for 21 July 2025. It provides shareholders with voting instructions, proxy appointment details, and resolutions to be voted on, which are hallmarks of proxy solicitation materials. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2025-06-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.